Sentinel Oncology win regional award


Sentinel Oncology was announced as the Discovery and Development category winner of the 2008 ERBI Biotech Regional Awards.

“We are delighted to be recognised by ERBI in receipt of this award for innovation in drug discovery“, said Bob Boyle, Director of Sentinel Oncology. “Our technology represents an exciting opportunity to develop new drugs that will offer improved treatment options for cancer patients”. The company has progressed from the early start-up phase and now has a strong pipeline of discovery programmes, all of which are relevant to the treatment of difficult to cure cancers.

The ERBI BIOTECH Regional Awards 2008 were announced during ERBI’s Winter Ball on Saturday 29th November which was held at Duxford’s Imperial War Museum. The Innovation in Drug Discovery & Development Award 2008 recognises the contribution a company makes to the UK's dominant position in the development of innovative new medicines.

Sentinel Oncology was founded at the beginning of 2005 by Bob Boyle, Stuart Travers and Gavin Simpson. In March 2006 Sentinel received investment from the Cambridge University Challenge Fund. At the same time the company appointed Professor Ashok Venkitaraman, at the Hutchison/MRC Research Centre, to the board of Sentinel Oncology as a non-Executive Director. During 2007 further funding was received from the Wellcome Trust as part of its Seeding Drug Discovery initiative.

Commenting on the award, Sentinel Oncology Director Stuart Travers said: “Sentinel Oncology focuses on the development of drugs that exploit tumour hypoxia and DNA response pathways. This is a novel approach that we have successfully developed in collaboration with a world class advisory network. Our ultimate goal is the discovery of drugs for untreatable cancers and we are honoured to be recognised by ERBI for our efforts”.

Sentinel Oncology:

Sentinel Oncology is a privately owned small molecule drug discovery company focusing on the discovery and development of new chemical entities for the treatment of cancer. Sentinel has built a pipeline of small molecules designed to target hallmarks of solid tumours. In particular Sentinel is developing small molecule inhibitors that are activated selectively under tumour Hypoxia (the low oxygen environment found in all solid tumours). Our vision is to develop drugs in oncology that are void of the systemic toxicities often associated with chemotherapeutics. The company was founded in 2005 and is located on the Cambridge Science Park, Cambridge, UK. .


For more information please see

Cambridge Enterprise Seed Funds:

Cambridge Enterprise Seed Funds provides funding for early stage businesses that have been founded by researchers at the University of Cambridge. Cambridge Enterprise Seed Funds comprises the University Challenge Fund and the University Venture Fund. The University Challenge Fund was established in 2000 as a result of a government initiative, with start up funds from the University of Cambridge, the Wellcome Trust, the Gatsby Foundation and the Office of Science & Technology. The University Venture Fund is owned by the University of Cambridge and is an evergreen fund generated from the proceeds of equity sales held by the University.

Cambridge Enterprise Seed Funds is part of Cambridge Enterprise Limited. Cambridge Enterprise Limited facilitates the commercial development of intellectual property (IP) developed at the University of Cambridge. Cambridge Enterprise is one of the United Kingdom’s leading knowledge transfer offices, licensing patents and other IP to existing companies, both large and small as well as to spinouts formed to exploit University technology. For the academic year ending 2007 60 licences and 95 consultancy contracts were signed. Cambridge Enterprise manages equity holdings in 72 companies. Total income for the year exceeded £6.0 million of which £5.4 million (88%) was returned to the University’s academics and departments.

Working together with angels, venture capital funds, University staff and students, Cambridge Enterprise facilitates the formation of around thirty new companies each year (about five of which are based on University-owned intellectual property) and further engages with the investment community through the Cambridge Enterprise Venture Partners which is a unique association of the Seed Funds with eleven VC funds and two Angel groups, so strengthening the pool of finance and expertise available to the most promising new ventures.

Further information on Cambridge Enterprise can be found at: and for further information please contact:

Shirley Jamieson

Head of Marketing

Cambridge Enterprise Limited

Tel: 01223 760 339



Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.

Cambridge Enterprise, University of Cambridge